What we currently call breast cancer should be thought of as 10 completely separate diseases, according to an international study which has been described as a "landmark". The categories could improve treatment by tailoring drugs for a patient's exact type of breast cancer and help predict survival more accurately. The study in Nature analysed breast cancers from 2,000 women [Abstract] . It will take at least three years for the findings to be used in hospitals. [more inside]
Followup to this post: A US District Court has ruled that Myriad Genetic's patents on breast cancer genes BRCA1 and BRCA2, which allow them to hold exclusive rights to a widely used genetic test for inherited breast and ovarian cancer susceptibility, are invalid. Genomics Law Report analyzes the ruling in two posts. The decision is likely to be challenged in a legal appeal — but if upheld, it could have huge implications for the biotechnology industry. [more inside]
Cracking the Cancer Code: We already know that all cancers are caused by DNA mutations acquired during a person's lifetime. But what mutations actually cause cancer? We may be one step closer to finding out. International research teams led by the Cancer Genome Project at the Wellcome Trust Sanger Institute have now mapped the entire genetic code of two of the most common human cancers: lung and skin (malignant melanoma). Their findings have the potential to revolutionize preventative and treatment therapies as well as pave the way for new early detection tests. More. [more inside]
On behalf of medical organizations, universities, & individual patients, pathologists and genetics researchers, the ACLU has filed a lawsuit against Utah-based Myriad Genetics and the US Patent and Trademark Office. Myriad holds the US patents to the BRCA1 and BRCA2 genes, associated with hereditary causes of breast and ovarian cancers. Their patents guarantee the company the right to prevent anyone else from testing or studying those genes, which the ACLU says is unconstitutional and inhibits researchers from finding treatments and cures. [more inside]
Devil facial tumor disease has ravaged the population of Tasmanian Devils in the last decade. DFTD is a transmissible cancer, i.e. the tumor cells themselves (which differ genetically from their host animal) are the agent responsible. The disease is spread by biting and other contact, and the resulting grotesque tumors interfere with feeding and lead to starvation. Poor immune response may be partially responsible. This is actually not the only such disease: canine transmissible venereal tumor is an analogue that has been known to be contagious since the 19th century. (CTVT, however, gets a proper immune response.) [more inside]
The evolutionary reason behind senescence^ is one of the great mysteries of biology. Now cancer researchers may have discovered the key to why we age.
Scientists in Australia have discovered a new gene. Called BRCA3, this genetic mutation causes up to 10% of the breast cancer cases which run within families. This breakthrough completes the search for the trilogy of gene mutations. The first two gene mutation markers were discovered in 1994 and 1995 respectively.
We may grow old because we don't get cancer. Researchers have identified a gene called p53 whose function is to minimize tumors, but it may also cause aging as a side effect.